Denne stilling som tekniker giver en unik mulighed for at deltage i udviklingen af Symphogens antistofprodukter. Stillingen er i Cell Culture-teamet og mere specifikt i den del af teamet, der arbejder med upstream-proces-udvikling.

Ready to shape the future of antibody production? Come join our Purification Team, part of the Drug Substance Development group within our CMC department. Together, we develop and transfer downstream processes that enable the production and clinical supply of antibody-based biologics—working closely with CDMOs and contributing to regulatory submissions.

Passionate about purifying the future of antibody therapies? At Symphogen, part of the global Servier Group, we're advancing innovative biologics through world-class science and strong collaboration. We're now hiring a Scientist in Downstream Process Development to support and improve antibody purification processes that power next-generation therapeutics.

This position as Technician offers a unique possibility to take part in the development of Symphogen’s antibody products. The position is in the Cell Culture team and more specifically in the part of the team that works with upstream process development.

Want to help shape the future of antibody therapies—hands-on and at the bench? At Symphogen, we combine cutting-edge science with a strong collaborative mindset. As part of the Servier Group, we focus on antibody-based innovations in oncology and immuno-inflammatory diseases.

Are you ready to lead innovation in antibody discovery as our new Principal Scientist? Join Symphogen, where world-class scientists and technologists collaborate to develop next-generation antibody-based therapies. As a key part of the Servier Group, we focus on scientific excellence and transformative R&D.

This position offers a unique opportunity to be part of a dedicated scientific team working in an innovative and important area within therapeutic antibodies. Come join our exceptional Analytical Development Team focused on monoclonal and bispecific antibodies, as well as antibody-drug conjugates (ADCs).